<DOC>
	<DOC>NCT00002322</DOC>
	<brief_summary>To determine the tolerance and antiviral response of two different doses of atevirdine mesylate (U-87201E) in symptomatic HIV-positive patients with CD4 counts of 50-350 cells/mm3, who also take zidovudine (AZT).</brief_summary>
	<brief_title>A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients</brief_title>
	<detailed_description>Patients are randomized to 1 of 3 treatment groups: U-87201E at 1 of 2 doses or placebo administered every 8 hours. Patients must have taken AZT for at least 3 months prior to randomization.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Atevirdine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication: Allowed: Primary or secondary prophylaxis for opportunistic infections. Patients must have: HIV infection. Symptoms (currently or prior to enrollment) included in Category B or C of CDC classification, although THE FOLLOWING CURRENT ACUTE MEDICAL CONDITIONS ARE NOT ALLOWED: Cryptococcosis Pneumocystis carinii pneumonia Herpes zoster Histoplasmosis CMV Hepatic or renal disease Lymphoma. CD4 count 50 350 cells/mm3 within 14 days prior to study entry. Ongoing therapy with AZT at 500 600 mg total daily dose for at least 3 months prior to study entry. Consent of parent, guardian, or person with power of attorney if less than 18 years of age. Exclusion Criteria Coexisting Condition: Patients with the following conditions are excluded: Intolerance to AZT. Current diagnosis of malignancy for which systemic therapy will be required during the study. Concurrent Medication: Excluded: Any other investigational drugs. Prior Medication: Excluded: Cytotoxic chemotherapy within 1 month prior to study entry. Prior U87201E or any other nonnucleoside antiretroviral medications, including but not limited to nevirapine, TIBO R82150 or TIBO R82913, L697639 or L696229, U90152S, or any protease inhibitors. Antiretroviral agents other than AZT within 3 months prior to study entry. Required: AZT for at least 3 months prior to study entry. Present use of excessive alcohol or illicit drugs.</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1996</verification_date>
	<keyword>Drug Therapy, Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>